Cumberland Pharmaceuticals Reports 38% Revenue Growth In The First Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cumberland Pharmaceuticals (CPIX) Reports In-Line Q1 EPS, Revs Beat
May 14, 2019 4:11 PM EDTCumberland Pharmaceuticals (NASDAQ: CPIX) reported Q1 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $11.9 million versus the consensus estimate of $10.7 million.
Quarter highlights:
Obtained FDA approval of our Next Generation Caldolor® product featuring a new patented... More